FMP
Enanta Pharmaceuticals, Inc.
ENTA
NASDAQ
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
6.65 USD
-0.18 (-2.71%)
ENTA Financial Statements
Year
2024
2023
2022
2021
Total Revenue
67.64M
79.2M
86.16M
97.07M
Cost of Revenue
0
0
2.97M
0
Gross Profit
67.64M
79.2M
83.19M
97.07M
Operating Expenses
189.33M
216.41M
210M
206.65M
Research and Development
131.48M
163.52M
164.52M
174.11M
Selling, General & Administrative Expenses
57.85M
52.89M
45.48M
32.54M
Selling & Marketing Expenses
0
0
0
0
General & Administrative Expenses
57.85M
52.89M
45.48M
32.54M
Other Expenses
0
0
83k
1.99M
Operating Income
-121.69M
-137.21M
-123.84M
-109.57M
Total Other Income/Expenses Net
3.9M
6.21M
1.66M
1.99M
Income Before Tax
-117.79M
-131M
-122.19M
-107.58M
Income Tax
-1.74M
2.82M
-433k
-28.58M
Net Income
-116.05M
-133.82M
-121.75M
-79M
Basic EPS
-5.48
-6.38
-5.91
-3.92
EPS Diluted
-5.48
-6.38
-5.91
-3.92
Basic Average Shares
21.16M
20.97M
20.6M
20.17M
Diluted Average Shares
21.16M
20.97M
20.6M
20.17M
EBITDA
-104.51M
-123.48M
-119.22M
-104.25M
Retained Earning Schedule
Year
2024
2023
2022
2021
Retained Earnings (Previous Year)
-207M
-73.18M
48.58M
127.57M
Net Income
-116.05M
-133.82M
-121.75M
-79M
Stock Repurchases
0
0
-1.23M
-534k
Dividend Paid
0
0
0
0
Retained Earnings
-323.04M
-207M
-73.18M
48.58M
Other Distributions
-116.05M
-133.82M
-122.98M
-79.53M
PPE Schedule
Year
2024
2023
2022
2021
Gross PPE
73.35M
34.71M
29.75M
10.65M
Annual Depreciation
2.34M
2.37M
2.97M
3.33M
Capital Expenditure
-17.95M
-9.06M
-2.13M
-750k
Net PPE
88.96M
41.4M
28.9M
8.07M
Intangible and Goodwill Schedule
Year
2024
2023
2022
2021
Acquisitions and Adjustments
0
0
0
0
Goodwill (Previous Year)
0
0
0
0
Goodwill
0
0
0
0
All figures are in USD.
